- The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of certolizumab pegol treatment in pediatric patients, aged 6 to 17, with moderately to severe active Crohn's disease. The target enrollment is 160 patients.
|